What's New SGLT2?: An update on the expanding scope with SGLT2 inhibitors

1. Describe the pathophysiology of sodium-glucose co-transporter 2 (SGLT2) inhibitors

2. Discuss the literature demonstrating the efficacy of SGLT2 inhibitors on cardiovascular and renal outcomes

3. Identify the safety for continuing as well as initiating therapy with SGLT2 inhibitors in patients with decreased renal function

4. Review the guideline recommendations and available literature to recommend therapy for patients with and without diabetes

12:00 p.m. to 12:10 p.m.        Welcome & Pre-test  

12:10 p.m. to 12:50 p.m.        Program Presentation

12:50 p.m. to 1:00 p.m.         Post-test and Q & A

Program components are:

• Pre-test
  
• Presentation
  
• Post-test
• Question and Answer session

Achieving a passing score of the assessment post-test is not a requirement of obtaining continuing education credit; however, participating in all active learning components is.

Christopher Brighton, PharmD

PGY1 Pharmacy Resident, UB Middleport Family Health Center

General Registration $25.00

We reserve the right to cancel this program due to such factors as insufficient registration. Registrants will be notified in this case. Requests for refunds, minus a $10 service charge, must be made in writing and will be honored up to one week prior to the program. After that time, no refunds will be provided.

Accreditaton information for pharmacists:

The University at Buffalo School of Pharmacy and Pharmaceutical Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based activity has been awarded 1 contact hour or 0.1 ceu of live continuing pharmacy education credit.  Credit will be uploaded to the CPE Monitor for attendees who complete all components of the activity.

"What's New SGLT2?:  An update on the expanding scope with SGLT2 inhibitors."

ACPE# 0044-0000-22-003-L01-P

1 Contact Hr. or 1 CEU.

Please email questions to pharmacyce@buffalo.edu